Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology.

Hochgräfe K, Sydow A, Mandelkow EM.

FEBS J. 2013 Sep;280(18):4371-81. doi: 10.1111/febs.12250. Epub 2013 Apr 22. Review.

2.

Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau.

Van der Jeugd A, Hochgräfe K, Ahmed T, Decker JM, Sydow A, Hofmann A, Wu D, Messing L, Balschun D, D'Hooge R, Mandelkow EM.

Acta Neuropathol. 2012 Jun;123(6):787-805. doi: 10.1007/s00401-012-0987-3. Epub 2012 Apr 25.

3.

The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.

Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, Petrova O, Schönig K, Bujard H, Mandelkow E, Zhou L, Rune G, Mandelkow EM.

J Neurosci. 2008 Jan 16;28(3):737-48. doi: 10.1523/JNEUROSCI.2824-07.2008.

4.

Reversibility of Tau-related cognitive defects in a regulatable FTD mouse model.

Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, D'Hooge R, Alzheimer C, Mandelkow EM.

J Mol Neurosci. 2011 Nov;45(3):432-7. doi: 10.1007/s12031-011-9604-5. Epub 2011 Aug 6.

PMID:
21822709
5.

Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant.

Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, D'Hooge R, Alzheimer C, Mandelkow EM.

J Neurosci. 2011 Feb 16;31(7):2511-25. doi: 10.1523/JNEUROSCI.5245-10.2011.

6.

The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy.

Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A, Schönig K, Bujard H, Haemisch A, Mandelkow E, Zhou L, Rune G, Mandelkow EM.

J Biol Chem. 2007 Oct 26;282(43):31755-65. Epub 2007 Aug 23.

7.

Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.

Hochgräfe K, Sydow A, Matenia D, Cadinu D, Könen S, Petrova O, Pickhardt M, Goll P, Morellini F, Mandelkow E, Mandelkow EM.

Acta Neuropathol Commun. 2015 May 10;3:25. doi: 10.1186/s40478-015-0204-4.

8.
9.

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, Behar L, Ben-Hur T, Avraham Y, Berry E, Segal M, Ginzburg I, Abramsky O.

Exp Neurol. 2008 Jul;212(1):71-84. doi: 10.1016/j.expneurol.2008.03.007. Epub 2008 Mar 21.

PMID:
18490011
10.

Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease.

Zhang Z, Song M, Liu X, Kang SS, Kwon IS, Duong DM, Seyfried NT, Hu WT, Liu Z, Wang JZ, Cheng L, Sun YE, Yu SP, Levey AI, Ye K.

Nat Med. 2014 Nov;20(11):1254-62. doi: 10.1038/nm.3700. Epub 2014 Oct 19.

11.

'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.

Sydow A, Mandelkow EM.

Neurodegener Dis. 2010;7(1-3):28-31. doi: 10.1159/000283479. Epub 2010 Feb 13.

PMID:
20160454
12.

Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca(++) dysregulation.

Decker JM, Krüger L, Sydow A, Zhao S, Frotscher M, Mandelkow E, Mandelkow EM.

Acta Neuropathol Commun. 2015 Apr 3;3:23. doi: 10.1186/s40478-015-0193-3.

13.

Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.

Umeda T, Maekawa S, Kimura T, Takashima A, Tomiyama T, Mori H.

Acta Neuropathol. 2014 May;127(5):685-98. doi: 10.1007/s00401-014-1259-1. Epub 2014 Feb 15.

PMID:
24531886
14.

A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.

Amadoro G, Corsetti V, Stringaro A, Colone M, D'Aguanno S, Meli G, Ciotti M, Sancesario G, Cattaneo A, Bussani R, Mercanti D, Calissano P.

J Alzheimers Dis. 2010;21(2):445-70. doi: 10.3233/JAD-2010-100120.

PMID:
20571215
15.

A rapid gene delivery-based mouse model for early-stage Alzheimer disease-type tauopathy.

Siman R, Lin YG, Malthankar-Phatak G, Dong Y.

J Neuropathol Exp Neurol. 2013 Nov;72(11):1062-71. doi: 10.1097/NEN.0000000000000006.

16.

Analysis of in vivo turnover of tau in a mouse model of tauopathy.

Yamada K, Patel TK, Hochgräfe K, Mahan TE, Jiang H, Stewart FR, Mandelkow EM, Holtzman DM.

Mol Neurodegener. 2015 Oct 26;10:55. doi: 10.1186/s13024-015-0052-5.

17.

Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice.

Peeraer E, Bottelbergs A, Van Kolen K, Stancu IC, Vasconcelos B, Mahieu M, Duytschaever H, Ver Donck L, Torremans A, Sluydts E, Van Acker N, Kemp JA, Mercken M, Brunden KR, Trojanowski JQ, Dewachter I, Lee VM, Moechars D.

Neurobiol Dis. 2015 Jan;73:83-95. doi: 10.1016/j.nbd.2014.08.032. Epub 2014 Sep 16.

18.

Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice.

Stancu IC, Vasconcelos B, Ris L, Wang P, Villers A, Peeraer E, Buist A, Terwel D, Baatsen P, Oyelami T, Pierrot N, Casteels C, Bormans G, Kienlen-Campard P, Octave JN, Moechars D, Dewachter I.

Acta Neuropathol. 2015 Jun;129(6):875-94. doi: 10.1007/s00401-015-1413-4. Epub 2015 Apr 11.

19.

Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model.

Fox LM, William CM, Adamowicz DH, Pitstick R, Carlson GA, Spires-Jones TL, Hyman BT.

J Neuropathol Exp Neurol. 2011 Jul;70(7):588-95. doi: 10.1097/NEN.0b013e318220a658.

20.

Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.

Koson P, Zilka N, Kovac A, Kovacech B, Korenova M, Filipcik P, Novak M.

Eur J Neurosci. 2008 Jul;28(2):239-46. doi: 10.1111/j.1460-9568.2008.06329.x.

PMID:
18702695

Supplemental Content

Support Center